{"database": "open_comments", "table": "documents", "rows": [["FDA-2026-N-10429-0001", "FDA", "FDA-2026-N-10429", "Design and Safety Considerations for Clinical Trials Involving Ibogaine Drug Products; Request for Information", "Notice", "Requests for Information (RFI)", "2026-10-06", 2026, 10, "2026-10-06", "2026-11-20", "2026-11-21 04:59:59", 0, "2026-11-18 10:00:52", "2026-20427", 1, 0, "09000064b962e7b9"]], "columns": ["id", "agency_id", "docket_id", "title", "document_type", "subtype", "posted_date", "posted_year", "posted_month", "comment_start_date", "comment_end_date", "comment_end_datetime", "perpetual_docket", "last_modified", "fr_doc_num", "open_for_comment", "withdrawn", "object_id"], "primary_keys": ["id"], "primary_key_values": ["FDA-2026-N-10429-0001"], "units": {}, "query_ms": 0.20417199993971735, "source": "U.S. government sources, plus a few identifier registries; each is listed on the methodology page", "source_url": "https://datadawn.org/methodology#data", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}